Analyst Ratings For Biogen (NASDAQ:BIIB)
Today, Leerink Swann reiterated its Market Perform rating on Biogen (NASDAQ:BIIB) with a price target of $338.00.
There are 11 hold ratings, 13 buy ratings, 1 strong buy rating on the stock.
The current consensus rating on Biogen (NASDAQ:BIIB) is Buy (Score: 2.60) with a consensus target price of $330.05 per share, a potential 16.64% upside.
Some recent analyst ratings include
- 7/26/2017-Leerink Swann Reiterated Rating of Market Perform.
- 7/26/2017-Goldman Sachs Group, Inc. (The) Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 7/18/2017-BMO Capital Markets Reiterated Rating of Hold.
- 7/11/2017-Jefferies Group LLC Reiterated Rating of Hold .
- 7/10/2017-Morgan Stanley Reiterated Rating of Equal Weight.
- 7/3/2017-Cowen and Company Reiterated Rating of Outperform.
Recent Insider Trading Activity For Biogen (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB) has insider ownership of 0.32% and institutional ownership of 87.50%.
- On 7/19/2017 Susan H Alexander, EVP, sold 7,758 with an average share price of $285.00 per share and the total transaction amounting to $2,211,030.00. View SEC Filing
- On 6/9/2017 Brian S Posner, Director, sold 1,084 with an average share price of $256.31 per share and the total transaction amounting to $277,840.04. View SEC Filing
- On 5/1/2017 Michel Vounatsos, CEO, bought 1,402 with an average share price of $271.35 per share and the total transaction amounting to $380,432.70. View SEC Filing
- On 4/27/2017 Alexander J. Denner, Director, bought 73,858 with an average share price of $278.50 per share and the total transaction amounting to $20,569,453.00. View SEC Filing
- On 4/25/2017 Paul J Clancy, VP, sold 9,892 with an average share price of $290.00 per share and the total transaction amounting to $2,868,680.00. View SEC Filing
- On 4/3/2017 Alfred Sandrock, CMO, sold 1,981 with an average share price of $274.08 per share and the total transaction amounting to $542,952.48. View SEC Filing
- On 3/13/2017 Paul J Clancy, VP, sold 9,891 with an average share price of $291.55 per share and the total transaction amounting to $2,883,721.05. View SEC Filing
Recent Trading Activity for Biogen (NASDAQ:BIIB)
Shares of Biogen closed the previous trading session at 282.96 down -1.74 -0.61% with 3,110,019 shares trading hands.